• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $MOVE

    Movano Inc.

    Subscribe to $MOVE
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Movano Inc., a technology company, develops a smart wearable and continuous glucose monitoring device. Its device enables individuals and their healthcare partners to measure and manage their health conditions. Movano Inc. was formerly known as Maestro Sensors Inc. and changed its name to Movano Inc. in August 2018. The company was incorporated in 2018 and is based in Pleasanton, California.

    IPO Year: 2021

    Exchange: NASDAQ

    Website: movano.com

    Recent Analyst Ratings for Movano Inc.

    DatePrice TargetRatingAnalyst
    See more ratings

    Movano Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Caballero Ruben bought 22,000 shares, increasing direct ownership by 38% to 80,200 units (SEC Form 4)

    4 - Movano Inc. (0001734750) (Issuer)

    4/12/24 4:30:19 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Fairbairn Emily bought 4,690,000 shares (SEC Form 4)

    4 - Movano Inc. (0001734750) (Issuer)

    4/4/24 5:30:08 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Cogan Jeremy bought 45,000 shares, increasing direct ownership by 6% to 780,649 units (SEC Form 4)

    4 - Movano Inc. (0001734750) (Issuer)

    4/4/24 5:30:14 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Cullinan Brian bought 44,000 shares, increasing direct ownership by 20% to 260,070 units (SEC Form 4)

    4 - Movano Inc. (0001734750) (Issuer)

    4/4/24 5:30:12 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Mastrototaro John bought 176,500 shares, increasing direct ownership by 153% to 291,642 units (SEC Form 4)

    4 - Movano Inc. (0001734750) (Issuer)

    4/4/24 5:30:05 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Fairbairn Emily bought $250,750 worth of shares (295,000 units at $0.85) (SEC Form 4)

    4 - Movano Inc. (0001734750) (Issuer)

    11/15/23 4:11:54 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Mastrototaro John bought $10,200 worth of shares (12,000 units at $0.85), increasing direct ownership by 12% to 115,142 units (SEC Form 4)

    4 - Movano Inc. (0001734750) (Issuer)

    11/15/23 4:07:17 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Cogan Jeremy bought $10,200 worth of shares (12,000 units at $0.85), increasing direct ownership by 2% to 735,649 units (SEC Form 4)

    4 - Movano Inc. (0001734750) (Issuer)

    11/15/23 4:04:56 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Movano Inc. SEC Filings

    View All

    Movano Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Movano Inc. (0001734750) (Filer)

    8/28/25 4:36:09 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Movano Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Movano Inc. (0001734750) (Filer)

    8/22/25 4:25:32 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form PRE 14A filed by Movano Inc.

    PRE 14A - Movano Inc. (0001734750) (Filer)

    8/19/25 5:21:30 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form NT 10-Q filed by Movano Inc.

    NT 10-Q - Movano Inc. (0001734750) (Filer)

    8/15/25 4:00:02 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Movano Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant

    8-K - Movano Inc. (0001734750) (Filer)

    8/15/25 8:30:26 AM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Movano Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

    8-K - Movano Inc. (0001734750) (Filer)

    8/7/25 4:05:32 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Movano Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Movano Inc. (0001734750) (Filer)

    7/11/25 5:21:55 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Movano Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    8-K - Movano Inc. (0001734750) (Filer)

    6/25/25 5:12:36 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Movano Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Movano Inc. (0001734750) (Filer)

    5/23/25 4:05:24 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form NT 10-Q filed by Movano Inc.

    NT 10-Q - Movano Inc. (0001734750) (Filer)

    5/21/25 5:22:02 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Movano Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Wirk Shaheen was granted 18,657 shares, increasing direct ownership by 64% to 47,727 units (SEC Form 4)

    4 - Movano Inc. (0001734750) (Issuer)

    7/3/25 4:30:38 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Executive Officer Mastrototaro John was granted 149,257 shares, increasing direct ownership by 154% to 246,221 units (SEC Form 4)

    4 - Movano Inc. (0001734750) (Issuer)

    7/3/25 4:30:33 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Fairbairn Emily was granted 27,985 shares, increasing direct ownership by 30% to 120,287 units (SEC Form 4)

    4 - Movano Inc. (0001734750) (Issuer)

    7/3/25 4:30:32 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Cullinan Brian was granted 29,851 shares, increasing direct ownership by 34% to 118,356 units (SEC Form 4)

    4 - Movano Inc. (0001734750) (Issuer)

    7/3/25 4:30:35 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Caballero Ruben was granted 18,657 shares, increasing direct ownership by 38% to 67,609 units (SEC Form 4)

    4 - Movano Inc. (0001734750) (Issuer)

    7/3/25 4:30:36 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Technology Officer Leabman Michael Aaron was granted 139,925 shares, increasing direct ownership by 184% to 216,163 units (SEC Form 4)

    4 - Movano Inc. (0001734750) (Issuer)

    7/3/25 4:30:39 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CFO Cogan Jeremy was granted 121,272 shares, increasing direct ownership by 105% to 236,300 units (SEC Form 4)

    4 - Movano Inc. (0001734750) (Issuer)

    7/3/25 4:30:28 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Caballero Ruben was granted 43,605 shares, increasing direct ownership by 816% to 48,952 units (SEC Form 4)

    4 - Movano Inc. (0001734750) (Issuer)

    5/13/25 4:30:14 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CFO Cogan Jeremy was granted 62,986 shares, increasing direct ownership by 121% to 115,028 units (SEC Form 4)

    4 - Movano Inc. (0001734750) (Issuer)

    5/13/25 4:30:12 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Executive Officer Mastrototaro John was granted 77,521 shares, increasing direct ownership by 399% to 96,964 units (SEC Form 4)

    4 - Movano Inc. (0001734750) (Issuer)

    5/13/25 4:30:12 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Movano Inc. Press Releases

    Fastest customizable press release news feed in the world

    View All

    Movano Health Granted Listing Extension by Nasdaq

    PLEASANTON, Calif., Aug. 28, 2025 /PRNewswire/ -- Movano Health (Nasdaq: MOVE)(the "Company") announced today that, by letter received on August 27, 2025, the Nasdaq Hearings Panel (the "Panel") of The Nasdaq Stock Market LLC ("Nasdaq") has determined to grant the Company's request to continue its listing on Nasdaq, subject to (i) the Company regaining compliance with Listing Rule 5250(c)(1), requiring the timely filing of periodic reports (the "Period Filing Rule"), by filing its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025 and June 30, 2025 on or before September 30, 2025, and (ii) the Company demonstrating compliance with Listing Rule 5550(a)(2), requiring the main

    8/28/25 4:30:00 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Movano Health Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

    PLEASANTON, Calif., Aug. 22, 2025 /PRNewswire/ -- Movano Health (Nasdaq: MOVE)(the "Company") announced today that it received a notice (the "Notice") from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq") indicating that because the Company had not yet filed its Form 10-Q for the quarterly period ended June 30, 2025 (the "Form 10-Q"), the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Filing Requirement") requiring Nasdaq-listed companies to timely file all periodic financial reports with the Securities and Exchange Commission (the "SEC"). The Form 10-Q was due on August 14, 2025.

    8/22/25 4:15:00 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Movano Health Plans to Timely Request a Hearing Before a Nasdaq Hearings Panel

    Received Delisting Notice from Nasdaq Related to Minimum Bid Price Requirement and Late Filing of the Form 10-Q for the period ended March 31, 2025 PLEASANTON, Calif., July 11, 2025 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) (the "Company") announced today that, on July 7, 2025, it received a delisting determination from The Nasdaq Capital Market with respect to the $1.00 per share bid price requirement (the "Bid Price Requirement"), as set forth in Listing Rule 5550(a)(2), and the late filing requirement, as set forth in Listing Rule 5250(c)(1), given the delay in filing its Form 10-Q for the quarter ended March 31, 2025 (the "Filing Requirement")(together, the "Notice"). Accordingly, the

    7/11/25 5:30:00 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Movano Health Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

    PLEASANTON, Calif., May 23, 2025 /PRNewswire/ -- Movano Health (Nasdaq: MOVE)(the "Company") announced today that it received a notice (the "Notice") from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq") indicating that because the Company had not yet filed its Form 10-Q for the quarterly period ended March 31, 2025 (the "Form 10-Q"), the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule") requiring Nasdaq-listed companies to timely file all periodic financial reports with the Securities and Exchange Commission (the "SEC"). The Form 10-Q was due on May 15, 2025.

    5/23/25 4:05:00 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Movano Health's Board of Directors Initiates Process to Maximize Shareholder Value

    PLEASANTON, Calif., May 16, 2025 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, announced today that its Board of Directors has initiated a process to explore strategic alternatives, including a sale, merger or similar transaction involving the Company, to maximize shareholder value.  To support this process, Movano Health's Board of Directors has engaged Aquilo Partners as its financial advisor and K&L Gates LLP as its legal counsel. There can be no assurance that this process will result in any transaction or other strategic change or as to the

    5/16/25 4:30:00 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Movano Health's Proprietary Cuffless Blood Pressure Device Once Again Achieves Accuracy Commensurate with the FDA's Requirements

    Leveraging the Company's System-on-a-Chip (SoC), the clinical study results are another significant step forward in commercializing a cuffless, radio frequency (RF)-enabled blood pressure device PLEASANTON, Calif., April 22, 2025 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, today announced positive results of its most recent 81-participant blood pressure clinical study. Movano Health's prototype demonstrated a level of accuracy well within the standards recognized by the FDA for blood pressure monitoring devices, achieving an overall mean absolute difference (MAD) of 4.9 mmHg, which significantly exceeds the 7 mmHg MAD threshold required per a standard for wea

    4/22/25 8:00:00 AM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Movano's Evie Ring Adds New Personalization and Trend Tracking to Support Women's Wellness Journey

    Upgrades Also Include Integration with Apple Health, Manual Post-Workout Logging PLEASANTON, Calif., March 10, 2025 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology and maker of the Evie Ring, today announced a series of new data personalization, trend tracking and integration features on the ring's companion app that expand support for women's wellness journeys. The enhancements follow January's beta release of EvieAI, the first wearable-based virtual wellness assistant built exclusively with training data from medical journals. Available immediate

    3/10/25 8:00:00 AM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Movano Health Commences Clinical Study with New Cuffless Blood Pressure Device

    New proprietary RF hardware delivers significantly enhanced signal fidelity PLEASANTON, Calif., Feb. 4, 2025 /PRNewswire/ -- Movano Health (NASDAQ:MOVE) announced today that it has commenced a blood pressure clinical trial with its newly developed cuffless blood pressure wrist wearable. The study, which is expected to include at least 70 participants and be completed during the second week of February, utilizes the updated device to monitor pulse pressure waveforms in comparison with a hospital grade blood pressure device. The new wearable will also collect data on a host of other vital signs including pulse rate, blood oxygen saturation (SpO2), respiration rate and ECG waveforms.

    2/4/25 8:00:00 AM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Movano Health Launches EvieAI Virtual Wellness Assistant

    Newest Evie Ring feature is the first medical journal trained AI companion in a wearable PLEASANTON, Calif., Jan. 8, 2025 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) today announced the latest enhancement to its Evie smart ring for women with the beta release of EvieAI, the first wearable-based virtual wellness assistant trained exclusively with data from medical journals. The new feature enables Evie users to answer health questions quickly, reliably and securely through the ring's companion app. Planned future integration with Evie data will allow EvieAI's responses to be p

    1/8/25 8:00:00 AM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Movano Health Welcomes Dr. Shaheen Wirk to its Board of Directors

    PLEASANTON, Calif., Jan. 2, 2025 /PRNewswire/ -- Movano Health (Nasdaq: MOVE), a pioneer in health technology, today announced the expansion of its board of directors with the addition of Dr. Shaheen Wirk, a leader in healthcare dedicated investment with a track record of success in medicine, partnerships, and research. With over 20 years of investment experience in public and private life science companies, Dr. Wirk is the founder and Chief Investment Officer of Palkon Capital Management, a healthcare dedicated investment firm launched in partnership with Julian Robertson and

    1/2/25 8:00:00 AM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Movano Inc. Financials

    Live finance-specific insights

    View All

    Movano Health Reports Q3 2024 Financial Results and Provides Business Update

    Highlights successful Evie Ring back-in-stock execution Updates status of EvieMED 510(k) application review Focuses on launch of EvieMED and securing B2B opportunities Conference Call at 2:00 PM PT/ 5:00 PM ET Today PLEASANTON, Calif., Nov. 14, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, reported third quarter 2024 results and provided a business update. The Company continues to remain focused on three key business initiatives. Successful execution of the Evie Ring direct-to-consumer business (D2C) following the September 17th back-in-sto

    11/14/24 4:05:00 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Movano Health Reports Q2 2024 Financial Results and Provides Business Update

    Prepares for September 17, 2024, Evie Ring back in stock dateAnnounces brand partnership with digital creator Heidi D'AmelioFocuses on launch of EvieMED and securing B2B opportunitiesConference Call at 2:00 PM PT/ 5:00 PM ET Today PLEASANTON, Calif., Aug. 14, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, reported second quarter 2024 results and provided a business update. Following the successful close of the Company's April 2024 $24.1 million private placement that included a seed investment from a tier 1 multi-billion dollar medical device

    8/14/24 4:05:00 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Movano Health Provides Progress Update on EvieMED Regulatory Filing

    Company continues to work with FDA to bring this pioneering healthcare product to market PLEASANTON, Calif., Aug. 5, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) plans to meet with the FDA in mid-August, as part of the Company's ongoing process to secure a 510(k) clearance for the EvieMED Ring, a wearable designed to not only provide medical device functionality through its pulse oximetry feature, but also offer numerous wellness metrics related to sleep, activity and mood/energy/symptom logging. On April 21, 2024, Movano Health filed an updated 510(k) for the EvieMED Ring's pulse oximetry feature. At the time of the filing and based on prior interactions with the agency and its protoco

    8/5/24 9:00:00 AM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Movano Health to Report Second Quarter 2024 Financial Results on Wednesday August 14, 2024

    Conference Call at 2:00 PM PT/ 5:00 PM ET PLEASANTON, Calif., Aug. 5, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, today announced that it will report second quarter 2024 financial and operating results on Wednesday, August 14, 2024, after the market close. Management will host a conference call and live audio webcast to discuss these results and provide a business update on the same day at 2:00 pm PT/5:00 pm ET. Attendees can access the live webcast here or on the investors section of Movano Health's website at https://ir.movano.com. The c

    8/5/24 9:00:00 AM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Movano Health Reports Q1 2024 Financial Results and Provides Business Update

    Submits exemplary Sp02 clinical trial results as part of FDA 510(k) clearance processPlans launch of Evie Med and focuses on B2B opportunitiesPlans arterial blood pressure study for JuneConference Call at 2:00 PM PT/ 5:00 PM ET Today PLEASANTON, Calif., May 15, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, reported first quarter 2024 results and provided a business update. Following the successful close of its recent $24 million private placement that included a seed investment from a tier 1 multi-billion dollar medical device company, Movan

    5/15/24 4:05:00 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Movano Health to Report First Quarter 2024 Financial Results on Wednesday May 15, 2024

    Conference Call at 2:00 PM PT/ 5:00 PM ET PLEASANTON, Calif., May 6, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, today announced that it will report first quarter 2024 financial and operating results on Wednesday May 15, 2024, after the market close. Management will host a conference call and live audio webcast to discuss these results and provide a business update on the same day at 2:00 pm PT/5:00 pm ET. Attendees can access the live webcast here or on the investors section of Movano Health's website at https://ir.movano.com. The confere

    5/6/24 5:00:00 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Movano Health Announces $24 Million Private Placement

    Financing included a strategic seed investment by a tier-1 multi-billion dollar medical device company and participation from members of Movano Health's management team and board of directors Hosting conference call on April 4, 2024 at 2:00 PM PT/5:00 PM ET PLEASANTON, Calif., April 2, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, today has agreed to sell approximately 45 million units in a $24 million private placement, with each unit consisting of one share of the Company's common stock (or pre-funded warrant in lieu thereof) and one warrant to purchase a share of common stock, to a select group of investors that includes a tier-one multi-billion dolla

    4/2/24 5:01:00 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Movano Health to Report Fourth Quarter 2023 Financial Results on Thursday, April 4, 2024

    Conference Call at 2:00 PM PT/ 5:00 PM ET PLEASANTON, Calif., April 2, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, today announced that it will report fourth quarter 2023 financial and operating results on Thursday, April 4, 2024, after the market close. Management will host a conference call and live audio webcast to discuss these results and provide a business update on the same day at 2:00 pm PT/5:00 pm ET. Attendees can access the live webcast here or on the investors section of Movano Health's website at https://ir.movano.com. The con

    4/2/24 4:05:00 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Movano Inc. to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023

    PLEASANTON, Calif., Aug. 8, 2023 /PRNewswire/ -- Movano Inc. (NASDAQ:MOVE) dba Movano Health, a purpose-driven healthcare solutions company at the intersection of medtech and consumer devices and makers of the Evie Ring, today announced that it will report second quarter 2023 financial and operating results on Monday, August 14, 2023. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 2:00 p.m. PDT (5:00 p.m. EDT).  Attendees can access the live webcast here or on the investors section of Movano Health's webs

    8/8/23 4:30:00 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Movano Health Provides Business Update and Reports Third Quarter 2022 Financial Results

    Conference call begins at 2:00 p.m. Pacific time today PLEASANTON, Calif., Nov. 14, 2022 /PRNewswire/ -- Today, Movano Inc. (NASDAQ:MOVE) dba Movano Health, a purpose-driven healthcare solutions company at the intersection of medical and consumer devices, reported financial results for the three months ending September 30, 2022 and provided a business update. Highlights from the third quarter and recent weeks include the following: Movano Health continues to expect to test the wearability and functionality of its smart device in beta programs with multiple strategic partners b

    11/14/22 4:30:00 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Movano Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Movano Inc.

    SC 13G - Movano Inc. (0001734750) (Subject)

    4/10/24 4:39:12 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Movano Inc. (Amendment)

    SC 13G/A - Movano Inc. (0001734750) (Subject)

    4/9/24 5:41:12 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Movano Inc.

    SC 13G - Movano Inc. (0001734750) (Subject)

    2/4/22 4:20:05 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Movano Inc.

    SC 13G - Movano Inc. (0001734750) (Subject)

    2/4/22 4:17:22 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care